Anticholinergic Burden Among In-patients: a Cross-sectional Study on Prevalence, Determinants, and Impact on Mortality in Ethiopia

Overview

Journal Ther Adv Drug Saf

Publisher Sage Publications

Date 2024 Jun 17

PMID 38881539

Authors

Eyob Alemayehu Gebreyohannes

Wagaye Atalay Taye

Biniam Siyum Shibe

Emneteab Mesfin Ayele

Kenneth Lee

Segenet Bizuneh Mengistu

Roy Louis Soiza

Phyo Kyaw Myint

Ousman Abubeker Abdela

Affiliations

Soon will be listed here.

Abstract

Background: Numerous studies report that anticholinergic burden (ACB) has been linked with several health consequences, including increased hospital admissions, prolonged hospitalization, and physical and cognitive impairment. However, low- and middle-income settings, as well as younger individuals, are underrepresented.

Objectives: To assess the prevalence and determinants of ACB, and to assess the impact of ACB on in-hospital mortality among adult in-patients at University of Gondar Comprehensive Specialized Hospital (UOGCSH).

Design: A cross-sectional study was conducted from June to August 2022 at UOGCSH among adult in-patients.

Methods: A pre-tested questionnaire was utilized to collect data from patients and their corresponding medical charts. A consecutive sampling technique was used to select the participants. Descriptive statistics were used to summarize socio-demographic and clinical characteristics. Chi-squared, Fisher's exact, and Wilcoxon rank sum tests, as appropriate, were used to determine associations between independent variables and ACB. Kaplan-Meier survival curve and Cox proportional hazards regression test were used to assess the impact of ACB on in-hospital mortality.

Results: A total of 420 adult in-patients, median (interquartile range) age of 38 (26, 55) years, participated in this study. Over half (58.3%) were exposed to anticholinergic medicines, with a high ACB (⩾3) seen in 11.2% of participants. High ACB was associated with higher median number of medicines per patient ( = 0.003) higher median hospital length of stay ( = 0.033), and having mental and behavioral disorders ( < 0.001). No significant association was found between ACB and in-hospital mortality (log-rank test = 0.26, Cox regression adjusted hazard ratio: 1.47, 95% CI: 0.335-6.453, = 0.61).

Conclusion: Among adult in-patients, a significant majority (58.3%) were subjected to medications possessing anticholinergic properties, with a noteworthy 11.2% of the study subjects exhibiting a high ACB. Participants with higher median length of hospital stay were more likely to have high ACB even in this relatively younger adult patient population.

References

Weichert I, Romero-Ortuno R, Tolonen J, Soe T, Lebus C, Choudhury S . Anticholinergic medications in patients admitted with cognitive impairment or falls (AMiCI). The impact of hospital admission on anticholinergic cognitive medication burden. Results of a multicentre observational study. J Clin Pharm Ther. 2018; 43(5):682-694. DOI: 10.1111/jcpt.12694. View

Lisibach A, Gallucci G, Beeler P, Csajka C, Lutters M . High anticholinergic burden at admission associated with in-hospital mortality in older patients: A comparison of 19 different anticholinergic burden scales. Basic Clin Pharmacol Toxicol. 2021; 130(2):288-300. PMC: 9299782. DOI: 10.1111/bcpt.13692. View

Salahudeen M, Nishtala P . Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research. Drugs Aging. 2016; 33(5):305-13. DOI: 10.1007/s40266-016-0362-5. View

Pourhoseingholi M, Vahedi M, Rahimzadeh M . Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2014; 6(1):14-7. PMC: 4017493. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007; 147(8):573-7. DOI: 10.7326/0003-4819-147-8-200710160-00010. View

Lechevallier-Michel N, Molimard M, Dartigues J, Fabrigoule C, Fourrier-Reglat A . Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. Br J Clin Pharmacol. 2005; 59(2):143-51. PMC: 1884748. DOI: 10.1111/j.1365-2125.2004.02232.x. View

Saz H, Yalcin N, Demirkan K, Halil M . Clinical pharmacist-led assessment and management of anticholinergic burden and fall risk in geriatric patients. BMC Geriatr. 2023; 23(1):863. PMC: 10724986. DOI: 10.1186/s12877-023-04599-2. View

Herrero-Zazo M, Berry R, Bines E, Bhattacharya D, Myint P, Keevil V . Anticholinergic burden in older adult inpatients: patterns from admission to discharge and associations with hospital outcomes. Ther Adv Drug Saf. 2021; 12:20420986211012592. PMC: 8111536. DOI: 10.1177/20420986211012592. View

Kidd A, Musonda P, Soiza R, Butchart C, Lunt C, Pai Y . The relationship between total anticholinergic burden (ACB) and early in-patient hospital mortality and length of stay in the oldest old aged 90 years and over admitted with an acute illness. Arch Gerontol Geriatr. 2014; 59(1):155-61. DOI: 10.1016/j.archger.2014.01.006. View

10.

Sumbul-Sekerci B, Bilgic B, Pasin O, Emre M, Hanagasi H . Anticholinergic Burden, Polypharmacy, and Cognition in Parkinson's Disease Patients with Mild Cognitive Impairment: A Cross-Sectional Observational Study. Dement Geriatr Cogn Disord. 2022; 51(5):386-395. PMC: 9909708. DOI: 10.1159/000526863. View

11.

Ang M, Abdul Rashid N, Lam M, Rapisarda A, Kraus M, Keefe R . The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia. J Clin Psychopharmacol. 2017; 37(6):651-656. PMC: 5680994. DOI: 10.1097/JCP.0000000000000790. View

12.

Fox C, Richardson K, Maidment I, Savva G, Matthews F, Smithard D . Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011; 59(8):1477-83. DOI: 10.1111/j.1532-5415.2011.03491.x. View

13.

Nishtala P, Salahudeen M, Hilmer S . Anticholinergics: theoretical and clinical overview. Expert Opin Drug Saf. 2016; 15(6):753-68. DOI: 10.1517/14740338.2016.1165664. View

14.

Lee J, Jung H, Jang I, Moon S, Lee S, Han S . Anticholinergic Cognitive Burden as a Predictive Factor for In-hospital Mortality in Older Patients in Korea. Ann Geriatr Med Res. 2020; 24(1):20-26. PMC: 7370777. DOI: 10.4235/agmr.19.0050. View

15.

Woodman R, Bryant K, Sorich M, Pilotto A, Mangoni A . Use of Multiprognostic Index Domain Scores, Clinical Data, and Machine Learning to Improve 12-Month Mortality Risk Prediction in Older Hospitalized Patients: Prospective Cohort Study. J Med Internet Res. 2021; 23(6):e26139. PMC: 8277374. DOI: 10.2196/26139. View

16.

Sevilla-Sanchez D, Molist-Brunet N, Gonzalez-Bueno J, Sola-Bonada N, Espaulella-Panicot J, Codina-Jane C . Prevalence, risk factors and adverse outcomes of anticholinergic burden in patients with advanced chronic conditions at hospital admission. Geriatr Gerontol Int. 2018; 18(8):1159-1165. DOI: 10.1111/ggi.13330. View

17.

Mate K, Kerr K, Pond D, Williams E, Marley J, Disler P . Impact of multiple low-level anticholinergic medications on anticholinergic load of community-dwelling elderly with and without dementia. Drugs Aging. 2015; 32(2):159-67. DOI: 10.1007/s40266-014-0230-0. View

18.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

19.

Masnoon N, Shakib S, Kalisch-Ellett L, Caughey G . What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1):230. PMC: 5635569. DOI: 10.1186/s12877-017-0621-2. View

20.

Ali S, Peterson G, Bereznicki L, Salahudeen M . Association between anticholinergic drug burden and mortality in older people: a systematic review. Eur J Clin Pharmacol. 2019; 76(3):319-335. DOI: 10.1007/s00228-019-02795-x. View